We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Medicines for Malaria Venture (MMV), Genzyme and the Broad Institute announced that they have expanded their collaboration to discover and advance new therapeutic candidates for malaria.
The FDA and the U.S. Federal Trade Commission (FTC), along with Health Canada and regulators in Mexico, have launched a drive to stop deceptive internet advertisements and sales of products misrepresented as cures or treatments for diabetes.
The German Federal Joint Committee has announced its decision on subsidizing sanofi-aventis' obesity drug Acomplia, recommending it be classified under Section 34 of the Social Code Volume, according to the company.
Korea-based Curocom is partnering with Canada's University of Western Ontario to develop an HIV vaccine that could be available for therapeutic use within three years and for use as a preventive vaccine within the next six years, according to the university.
An experimental vaccine that attacks the malaria parasite in its early stages prevents a significant number of malaria cases and should move closer to licensing and widespread use, according to a review of recent studies reported by Newswise.
The Canadian government has amended its Food and Drug Regulations to extend the period of guaranteed market exclusivity for new drugs from five to at least eight years, with an additional six-month extension for drugs that have undergone clinical trials on pediatric populations.
GlaxoSmithKline (GSK) announced it has signed a supply with the Swiss Federal Office of Public Health for 8 million doses of GSK's H5N1 antigen influenza vaccine and its proprietary adjuvant for pre-pandemic use.
Indian drugmaker Panacea Biotec has announced its initiative to develop and manufacture a dengue vaccine for the global prevention of dengue infection, the second most widespread tropical disease after malaria, according to the company.
Researchers at Makerere University in Uganda, along with scientists from Johns Hopkins University and other institutions, have begun the first clinical trial in Africa of a vaccine to prevent mother-to-child transmission of HIV through breastfeeding.